Share：
Share this content in WeChat
X
[Chinese][PDF]823
• Review •
Application status of tumor regression grading method after neoadjuvant chemoradiotherapy based on magnetic resonance imaging for locally advanced rectal cancer
HE Hong  CHEN Siyu  HU Fubi 

Cite this article as: HE H, CHEN S Y, HU F B. Application status of tumor regression grading method after neoadjuvant chemoradiotherapy based on magnetic resonance imaging for locally advanced rectal cancer[J]. Chin J Magn Reson Imaging, 2024, 15(7): 204-209. DOI:10.12015/issn.1674-8034.2024.07.034.


[Abstract] As the incidence and mortality rates of colorectal cancer continue to rise globally, the treatment strategies for locally advanced rectal cancer (LARC) have garnered widespread attention. Currently, total mesorectal excision (TME) following neoadjuvant chemoradiotherapy (NCRT) is recommended as the standard treatment protocol for LARC. Although NCRT can significantly improve outcomes, there is notable variability in LARC patient responses to this treatment. Therefore, accurately assessing the efficacy of NCRT is crucial for clinical decision-making and personalized medicine. Current methods for assessing treatment efficacy include serum tumor markers, endoscopy, endorectal ultrasound, and CT/MRI, each with its limitations. In recent years, the magnetic resonance tumor regression grade (mrTRG) has gained attention and recommendation for its advantages of radiation-free, multi-directional imaging, high soft tissue resolution and dynamic continuous observation. Hence, this article aims to analyze the latest domestic and foreign research literature, and focus on the research value and current status of mrTRG after NCRT in LARC patients.
[Keywords] locally advanced rectal cancer；neoadjuvant chemoradiotherapy；magnetic resonance imaging；tumor regression grading

HE Hong   CHEN Siyu   HU Fubi*  

Department of Radiology, The First Affiliated Hospital of Chengdu Medical College, Chengdu 610000, China

Corresponding author: HU F B, E-mail: yingxianghu_cmc@163.com

Conflicts of interest   None.

Received  2024-03-20
Accepted  2024-07-09
DOI: 10.12015/issn.1674-8034.2024.07.034
Cite this article as: HE H, CHEN S Y, HU F B. Application status of tumor regression grading method after neoadjuvant chemoradiotherapy based on magnetic resonance imaging for locally advanced rectal cancer[J]. Chin J Magn Reson Imaging, 2024, 15(7): 204-209. DOI:10.12015/issn.1674-8034.2024.07.034.

[1]
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]
ZHENG R S, CHEN R, HAN B F, et al. Cancer incidence and mortality in China, 2022[J]. Chin J Oncol, 2024, 46(3): 221-231. DOI: 10.3760/cma.j.cn112152-20240119-00035.
[3]
WANG X S. Discussion of the importance of early diagnosis and treatment of colorectal cancer from the epidemiological characteristics of colorectal cancer in China and United States of America[J]. Chin J Colorectal Dis Electron Ed, 2021, 10(1): 26-33. DOI: 10.3877/cma.j.issn.2095-3224.2021.01.004.
[4]
PENG J J, ZHU J, LIU F Q, et al. Expert consensus on diagnosis and treatment of locally advanced rectal cancer in China[J]. China Oncol, 2017, 27(1): 41-80. DOI: 10.19401/j.cnki.1007-3639.2017.01.008.
[5]
BENSON A B, VENOOK A P, AL-HAWARY M M, et al. Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(10): 1139-1167. DOI: 10.6004/jnccn.2022.0051.
[6]
MAAS M, NELEMANS P J, VALENTINI V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data[J]. Lancet Oncol, 2010, 11(9): 835-844. DOI: 10.1016/S1470-2045(10)70172-8.
[7]
VAN DER VALK M J M, HILLING D E, BASTIAANNET E, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study[J]. Lancet, 2018, 391(10139): 2537-2545. DOI: 10.1016/S0140-6736(18)31078-X.
[8]
KARLSSON L, BOCK D, ASPLUND D, et al. Urinary dysfunction in patients with rectal cancer: a prospective cohort study[J]. Colorectal Dis, 2020, 22(1): 18-28. DOI: 10.1111/codi.14784.
[9]
KOH C E, BROWN K G M, STEFFENS D, et al. What constitutes a clear margin in patients with locally recurrent rectal cancer undergoing pelvic exenteration?[J]. Ann Surg, 2022, 275(1): 157-165. DOI: 10.1097/SLA.0000000000003834.
[10]
LI G B, HAN J G, WANG Z J, et al. Efficacy of neoadiuvant chemoradiotherapy for locally advanced rectalcancer: are trospective study[J]. Chin J Pract Surg, 2021, 41(2): 184-189, 193. DOI: 10.19538/j.cjps.issn1005-2208.2021.02.15.
[11]
RULLIER E, VENDRELY V, ASSELINEAU J, et al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial[J]. Lancet Gastroenterol Hepatol, 2020, 5(5): 465-474. DOI: 10.1016/S2468-1253(19)30410-8.
[12]
MANDARD A M, DALIBARD F, MANDARD J C, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations[J]. Cancer, 1994, 73(11): 2680-2686. DOI: 10.1002/1097-0142(19940601)73:11<2680:aid-cncr2820731105>3.0.co;2-c.
[13]
DWORAK O, KEILHOLZ L, HOFFMANN A. Pathological features of rectal cancer after preoperative radiochemotherapy[J]. Int J Colorectal Dis, 1997, 12(1): 19-23. DOI: 10.1007/s003840050072.
[14]
EDGE S B, COMPTON C C. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM[J]. Ann Surg Oncol, 2010, 17(6): 1471-1474. DOI: 10.1245/s10434-010-0985-4.
[15]
MAAS M, LAMBREGTS D M, NELEMANS P J, et al. Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment[J]. Ann Surg Oncol, 2015, 22(12): 3873-3880. DOI: 10.1245/s10434-015-4687-9.
[16]
Image Big Data Artificial Intelligence Working Committee of Chinese Society of Radiology Chinese Medical Association, Abdominal Group of Chinese Society of Radiology Chinese Medical Association, Magnetic Resonance Imaging Group of Chinese Society of Radiology Chinese Medical Association. Expert consensus on the colorectal cancer annotation of CT and MRI (2020)[J]. Chin J Radiol, 2021, 55(2): 111-116. DOI: 10.3760/cma.j.cn112149-20200706-00894.
[17]
PATEL U B, TAYLOR F, BLOMQVIST L, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: mercury experience[J]. J Clin Oncol, 2011, 29(28): 3753-3760. DOI: 10.1200/JCO.2011.34.9068.
[18]
JANG J K, CHOI S H, PARK S H, et al. MR tumor regression grade for pathological complete response in rectal cancer post neoadjuvant chemoradiotherapy: a systematic review and meta-analysis for accuracy[J]. Eur Radiol, 2020, 30(4): 2312-2323. DOI: 10.1007/s00330-019-06565-2.
[19]
POPIŢA A R, RUSU A, MUNTEAN V, et al. Preoperative MRI accuracy after neoadjuvant chemoradiation for locally advanced rectal cancer[J]. Med Pharm Rep, 2023, 96(3): 258-268. DOI: 10.15386/mpr-2542.
[20]
SCLAFANI F, BROWN G, CUNNINGHAM D, et al. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer[J]. Ann Oncol, 2016, 27(8): 1557-1565. DOI: 10.1093/annonc/mdw215.
[21]
IANNICELLI E, PIETROPAOLO M D, PILOZZI E, et al. Value of diffusion-weighted MRI and apparent diffusion coefficient measurements for predicting the response of locally advanced rectal cancer to neoadjuvant chemoradiotherapy[J]. Abdom Radiol, 2016, 41(10): 1906-1917. DOI: 10.1007/s00261-016-0805-9.
[22]
LAMBREGTS D M, VANDECAVEYE V, BARBARO B, et al. Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study[J]. Ann Surg Oncol, 2011, 18(8): 2224-2231. DOI: 10.1245/s10434-011-1607-5.
[23]
SONG I, KIM S H, LEE S J, et al. Value of diffusion-weighted imaging in the detection of viable tumour after neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer: comparison with T2 weighted and PET/CT imaging[J]. Br J Radiol, 2012, 85(1013): 577-586. DOI: 10.1259/bjr/68424021.
[24]
ZHANG X Y, LI X T, SHI Y J, et al. High resolution MR T2WI combined with DWI in evaluation of pathological complete response after neoadjuvant therapy in rectal cancer[J]. Chin J Interv Imag Ther, 2017, 14(3): 164-168. DOI: 10.13929/j.1672-8475.201612020.
[25]
LEE M A, CHO S H, SEO A N, et al. Modified 3-point MRI-based tumor regression grade incorporating DWI for locally advanced rectal cancer[J]. AJR Am J Roentgenol, 2017, 209(6): 1247-1255. DOI: 10.2214/AJR.16.17242.
[26]
Colorectal Cancer Diagnosis and Treatment Technology Professional Committee of Chinese Medical Doctor Association, Abdomen Group Chinese Society of Radiology Chinese Medical Association. Expert consensus on MR examination and structured report of rectal cancer[J]. Chin J Radiol, 2021, 55(11): 1121-1127. DOI: 10.3760/cma.j.cn112149-20210518-00490.
[27]
GOLLUB M J, BLAZIC I, FELDER S, et al. Value of adding dynamic contrast-enhanced MRI visual assessment to conventional MRI and clinical assessment in the diagnosis of complete tumour response to chemoradiotherapy for rectal cancer[J]. Eur Radiol, 2019, 29(3): 1104-1113. DOI: 10.1007/s00330-018-5719-1.
[28]
POPITA A R, LISENCU C, RUSU A, et al. MRI evaluation of complete and near-complete response after neoadjuvant therapy in patients with locally advanced rectal cancer[J/OL]. Diagnostics, 2022, 12(4): 921 [2024-01-05]. https://pubmed.ncbi.nlm.nih.gov/35453969/. DOI: 10.3390/diagnostics12040921.
[29]
GUAN Z, SUN R J, CAO W T, et al. Magnetic resonance imaging tumor response score (mrTRS) predicts therapeutic effect and prognosis of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a prospective, multi-center study[J]. Radiother Oncol, 2020, 151: 288-295. DOI: 10.1016/j.radonc.2020.08.028.
[30]
YOEN H, PARK H E, KIM S H, et al. Prognostic value of tumor regression grade on MR in rectal cancer: a large-scale, single-center experience[J]. Korean J Radiol, 2020, 21(9): 1065-1076. DOI: 10.3348/kjr.2019.0797.
[31]
El KHABABI N, BEETS-TAN R G H, TISSIER R, et al. Comparison of MRI response evaluation methods in rectal cancer: a multicentre and multireader validation study[J]. Eur Radiol, 2023, 33(6): 4367-4377. DOI: 10.1007/s00330-022-09342-w.
[32]
CHANDRAMOHAN A, SIDDIQI U M, MITTAL R, et al. Diffusion weighted imaging improves diagnostic ability of MRI for determining complete response to neoadjuvant therapy in locally advanced rectal cancer[J/OL]. Eur J Radiol Open, 2020, 7: 100223 [2024-01-05]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044654. DOI: 10.1016/j.ejro.2020.100223.
[33]
SIDDIQUI M R, GORMLY K L, BHODAY J, et al. Interobserver agreement of radiologists assessing the response of rectal cancers to preoperative chemoradiation using the MRI tumour regression grading (mrTRG)[J]. Clin Radiol, 2016, 71(9): 854-862. DOI: 10.1016/j.crad.2016.05.005.
[34]
VAN DEN BROEK J J, VAN DER WOLF F S, LAHAYE M J, et al. Accuracy of MRI in restaging locally advanced rectal cancer after preoperative chemoradiation[J]. Dis Colon Rectum, 2017, 60(3): 274-283. DOI: 10.1097/DCR.0000000000000743.
[35]
SCLAFANI F, BROWN G, CUNNINGHAM D, et al. Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer[J]. Br J Cancer, 2017, 117(10): 1478-1485. DOI: 10.1038/bjc.2017.320.
[36]
PANG X L, XIE P Y, YU L, et al. A new magnetic resonance imaging tumour response grading scheme for locally advanced rectal cancer[J]. Br J Cancer, 2022, 127(2): 268-277. DOI: 10.1038/s41416-022-01801-x.
[37]
NIU S Q, CHEN Y, PENG F, et al. The role of MRI after neochemoradiotherapy in predicting pathological tumor regression grade and clinical outcome in patients with locally advanced rectal adenocarcinoma[J/OL]. Front Oncol, 2023, 13: 1118518 [2024-01-05]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292078. DOI: 10.3389/fonc.2023.1118518.
[38]
ACHILLI P, MAGISTRO C, AZIZ M A ABD EL, et al. Modest agreement between magnetic resonance and pathological tumor regression after neoadjuvant therapy for rectal cancer in the real world[J]. Int J Cancer, 2022, 151(1): 120-127. DOI: 10.1002/ijc.33975.
[39]
NIU D F, XUE W C. Pathological evaluation after preoperative neoadjuvant treatment in rectal cancer[J]. Chin J Gastrointest Surg, 2018, 21(6): 632-636. DOI: 10.3760/cma.j.issn.1671-0274.2018.06.003.
[40]
CHEN H Y, FENG L L, LI M, et al. College of American pathologists tumor regression grading system for long-term outcome in patients with locally advanced rectal cancer[J/OL]. Oncologist, 2021, 26(5): e780-e793 [2024-01-05]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100558. DOI: 10.1002/onco.13707.

PREV Overview of MRI-based radiomics in breast cancer diagnosis and treatment
NEXT Progress of quantitative prediction of the pathologic complete response after neoadjuvant chemoradiotherapy for locally advanced rectal cancer with functional MRI
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn